Printer Friendly

IVAX ANNOUNCES APPOINTMENTS OF OFFICERS

 IVAX ANNOUNCES APPOINTMENTS OF OFFICERS
 MIAMI, May 11 /PRNewswire/ -- IVAX Corporation (AMEX: IVX)


announced today the appointment of several officers. Charles Hsiao, Ph.D. was appointed to the position of vice chairman-Pharmaceutical Development. Jane Hsiao, Ph.D. was appointed to the position of chief regulatory officer and assistant to the chairman. Brian Tambi was appointed to the position of executive vice president. He will also serve as president of IVAX' North American Pharmaceutical Group and president of IVAX' wholly owned subsidiary, Baker Cummins Pharmaceuticals, Inc. Cynthia Yost was appointed to the position of vice president-Marketing of Baker Cummins Pharmaceuticals, Inc.
 Dr. Charles Hsiao is one of the founders of Baker Cummins Pharmaceuticals and has served as its president since its inception in 1986. Dr. Jane Hsiao has served Baker Cummins Pharmaceuticals since its inception as vice president-Regulatory Affairs, Quality Assurance and Quality Control. Both will join IVAX' newly created Office of Chairman. Dr. Charles Hsiao will also serve on IVAX' Operating Committee. He is also a member of IVAX' board of directors and the Executive Committee of the board of director.
 Tambi was most recently employed by Fujisawa Pharmaceutical Company, U.S.A. as its president and chief operating officer. Prior to joining Fujisawa, Tambi spent 13 years with Bristol-Myers Company in various management positions until he joined Lyphomed, Inc. in 1986 to create a brand name pharmaceutical business which was established and became operational in 1989. After Lyphomed was acquired by Fujisawa Pharmaceutical Company, Japan, in 1990 Tambi was charged with the responsibility of establishing Fujisawa Pharmaceutical Company, U.S.A. as a research and development based company which was successfully accomplished by 1991.
 Yost was most recently employed by Fujisawa Pharmaceutical Company, U.S.A. as director of marketing, a position she has held since 1989. She has previously served in various management positions for Lyphomed and Bristol-Myers.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescriptions and over the counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Willen Drug Company, a urological products company; DVM Pharmaceuticals Inc., a veterinary products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 5/11/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation ST: Florida IN: MTC SU: PER


SS-JB -- FL013 -- 8667 05/11/92 13:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1992
Words:469
Previous Article:ADAPTEC AND COREL JOIN FORCES TO MARKET NEW SCSI SOLUTIONS
Next Article:HELEN OF TROY REPORTS YEAR END/FOURTH QUARTER SALES AND EARNINGS
Topics:


Related Articles
IVAX ANNOUNCES RECORD EARNINGS
IVAX ANNOUNCES RECORD EARNINGS
IVAX ANNOUNCES PROPOSED ACQUISITION OF THE INDUSTRIAL AND INSTITUTIONAL CLEANING PRODUCTS BUSINESS OF ELF ATOCHEM NORTH AMERICA, INC.
PHILLIP FROST FILES HART-SCOTT-RODINO NOTICE RELATING TO POSSIBLE ACQUISITION OF IVAX SHARES
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
IVAX ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT BAKER NORTON PHARMACEUTICALS
IVAX CORPORATION APPOINTS DR. SAMUEL BRODER AS CHIEF SCIENTIFIC OFFICER
IVAX APPOINTS NEW VICE PRESIDENTS
IVAX Corporation Appoints Robert C. Strauss as President and Chief Operating Officer
IVAX Sells Textile Products Business to Sybron Chemicals

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters